patent/GR-1010126-B

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_082c49592d104a4189c1c9b88de2f052
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
filingDate	2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_031e9c66be59f7b4c0eae78635571175
publicationDate	2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	GR-1010126-B
titleOfInvention	FENDLINE AGAINST NEUROGYSTEMIC OR NEURODEVELOPING DISEASES AND CANCER DEVELOPMENT CO COVID-19 VIRUS
abstract	The present invention relates to the original pharmacological profile of 3,3-diphenyl-N- (1-phenylylthol) propan-1-amine (Fendiline) and its novel potential brain protective properties in neurodegenerative and neurodevelopmental diseases as well as in the development of cancer. or COVID-19 virus, through Fendilime antagonism against sigma-1 receptors.
priorityDate	2020-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014031755-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5506231-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018193289-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GR-1007853-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013296438-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID18391 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID10280 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29336 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID446848 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3336 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100135589 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419495016

Total number of triples: 25.